0001193125-23-286690.txt : 20231201 0001193125-23-286690.hdr.sgml : 20231201 20231201060630 ACCESSION NUMBER: 0001193125-23-286690 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231130 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231201 DATE AS OF CHANGE: 20231201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIORA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001580063 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273950390 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39334 FILM NUMBER: 231457456 BUSINESS ADDRESS: STREET 1: 4330 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92122 BUSINESS PHONE: 855-293-2639 MAIL ADDRESS: STREET 1: 4330 LA JOLLA VILLAGE DRIVE STREET 2: SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92122 FORMER COMPANY: FORMER CONFORMED NAME: PROGENITY, INC. DATE OF NAME CHANGE: 20150617 FORMER COMPANY: FORMER CONFORMED NAME: ASCENDANT MDX, INC. DATE OF NAME CHANGE: 20130625 8-K 1 d23829d8k.htm 8-K 8-K
false 0001580063 0001580063 2023-11-30 2023-11-30

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 30, 2023

 

 

Biora Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-39334   27-3950390

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

4330 La Jolla Village Drive, Suite 300  
San Diego, California   92122
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s Telephone Number, Including Area Code: (833) 727-2841

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange

on which registered

Common Stock, par value $0.001 per share   BIOR   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 8.01.

Other Events.

On November 30, 2023, Biora Therapeutics, Inc. issued a press release announcing clearance by the U.S. Food and Drug Administration of its Investigational New Drug application for BT-600, a drug/device combination for the treatment of moderate to severe ulcerative colitis. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits.

 

99.1    Press Release, dated November 30, 2023
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

      Biora Therapeutics, Inc.
Date: December 1, 2023     By:  

/s/ Eric d’Esparbes

     

Eric d’Esparbes

Chief Financial Officer

 EX-99.1 2 d23829dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination

BT-600 Targeting Treatment of Ulcerative Colitis

BT-600 will deliver a proprietary liquid formulation of tofacitinib via the NaviCap™ device for topical delivery to the colon

SAN DIEGO, November 30, 2023 – Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for BT-600, a drug/device combination for the treatment of moderate to severe ulcerative colitis.

“The FDA has agreed with our plans to proceed with clinical development of BT-600 and has activated our IND application. We appreciate the agency’s collaborative relationship as they have worked with us to achieve what is, to our knowledge, the first active IND for an ingestible drug and device combination,” said Ariella Kelman, MD, Chief Medical Officer of Biora Therapeutics. “We believe our therapeutic approach could lead to better outcomes for patients suffering from ulcerative colitis. We look forward to completing the activities required by FDA and the trial site prior to enrolling the first subject in our phase 1 clinical trial in the United States in the coming weeks.”

BT-600 is a drug/device combination designed to use Biora’s NaviCap™ ingestible drug delivery device with a proprietary liquid formulation of tofacitinib, for the treatment of moderate to severe ulcerative colitis. The NaviCap device has been designed for targeted delivery directly to the colon in this application. The phase 1 trial of BT-600 is planned as a randomized, double-blind, placebo-controlled, single and multiple ascending dose study to evaluate safety, pharmacokinetics and pharmacodynamics, including effects on colon tissue, in healthy volunteers receiving BT-600 with tofacitinib at 5 mg and 10 mg doses.

About the NaviCap™ Targeted Oral Delivery Platform and BT-600 

Biora’s NaviCap targeted oral therapeutics platform utilizes a novel approach that could improve patient outcomes by enabling delivery of therapeutics directly to the site of disease, increasing therapeutic levels in tissue while reducing systemic uptake. For the 1.8 million patients in the United States who suffer from inflammatory bowel disease (IBD), existing therapeutics offer less than ideal efficacy, likely because of the challenges with safely achieving sufficient drug levels in the affected tissues. Research has shown that targeted delivery of therapeutics has the potential to improve patient outcomes in IBD.

The NaviCap platform uses an ingestible device designed for targeted delivery of therapeutics to improve treatment of IBD. Once swallowed, Biora’s GItrac™ autolocation technology enables the device to autonomously identify targeted locations in the GI tract and release a therapeutic dose of up to 500µl.    

Biora’s BT-600 program consists of a unique, liquid formulation of tofacitinib delivered to the colon via the NaviCap device, for the treatment of ulcerative colitis. Studies in healthy volunteers have demonstrated accurate localization and delivery in a fasted state and demonstrated the device’s ability to function in both fasted and fed states, making it potentially the first ingestible therapeutic delivery device that does not require fasting or other food restriction for use. A device function study in participants with active ulcerative colitis (UC) also demonstrated successful device performance in active UC patients.

LOGO

 

About Biora Therapeutics

Biora Therapeutics is reimagining therapeutic delivery. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients’ lives.

Biora is focused on development of two therapeutics platforms: the NaviCap™ targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract, and the BioJet™ systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules.

For more information, visit bioratherapeutics.com or follow the company on LinkedIn or Twitter.

Safe Harbor Statement or Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development and clinical efforts including phase 1 trial readiness, phase 1 trial execution timeline, phase 1 trial commencement, and working through the final FDA and trial site requirements prior to enrolling the first subject, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan,” “target,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future filings and initiate clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval, clearance, or acceptance of our clinical trials or products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators, our ability to raise sufficient capital to achieve our business objectives, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC and other subsequent documents, including Quarterly Reports, that we file with the SEC.

LOGO

 

Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact

Chuck Padala

Managing Director, LifeSci Advisors

IR@bioratherapeutics.com

(646) 627-8390

Media Contact

media@bioratherapeutics.com

EX-101.SCH 3 bior-20231130.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 bior-20231130_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 bior-20231130_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g23829g1201061648661.jpg GRAPHIC begin 644 g23829g1201061648661.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Nov. 30, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001580063
Document Type 8-K
Document Period End Date Nov. 30, 2023
Entity Registrant Name Biora Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39334
Entity Tax Identification Number 27-3950390
Entity Address, Address Line One 4330 La Jolla Village Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92122
City Area Code (833)
Local Phone Number 727-2841
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol BIOR
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 8 d23829d8k_htm.xml IDEA: XBRL DOCUMENT 0001580063 2023-11-30 2023-11-30 false 0001580063 8-K 2023-11-30 Biora Therapeutics, Inc. DE 001-39334 27-3950390 4330 La Jolla Village Drive Suite 300 San Diego CA 92122 (833) 727-2841 false false false false Common Stock, par value $0.001 per share BIOR NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports bior-20231130.xsd bior-20231130_lab.xml bior-20231130_pre.xml d23829d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d23829d8k.htm": { "nsprefix": "bior", "nsuri": "http://bioratherapeutics.com/20231130", "dts": { "schema": { "local": [ "bior-20231130.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "bior-20231130_lab.xml" ] }, "presentationLink": { "local": [ "bior-20231130_pre.xml" ] }, "inline": { "local": [ "d23829d8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-11-30_to_2023-11-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d23829d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-11-30_to_2023-11-30", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d23829d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://bioratherapeutics.com//20231130/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001193125-23-286690-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-286690-xbrl.zip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end